An array of AI-powered features and automated tools may lead to improved workflow and image quality with the Voluson Expert 22, 20 and 18 ultrasound systems.
The Food and Drug Administration (FDA) has granted 510(k) clearance for artificial intelligence (AI) updates to the Voluson Expert Series of ultrasound systems geared toward examination of women with high-risk pregnancies.
New AI-enabled features with the Voluson Expert 22, 20 and 18 ultrasound systems include SonoLystlive, which facilitates increased accuracy for 11 to 14-week anatomical exams, and Graphicflow, which offers real-time visualization of blood flow trajectory that aids in detecting abnormal hemodynamics, according to GE HealthCare, the manufacturer of the Voluson Expert ultrasound platforms.
New artificial intelligence (AI) updates to the Voluson Expert 22, 20 and 18 ultrasound systems have garnered 510(k) clearance from the FDA. (Image courtesy of GE HealthCare.)
The company said other benefits include live C-plane tracking and automated plane alignment with SonoPelvicFloor3.0, which reportedly decreases exam time for pelvic floor measurement by 80 percent.
“We are proud to introduce these updates to the Voluson Expert ultrasound systems, which represent our ongoing commitment to advancing technology that addresses women's health needs of today, and the future,” noted Gerald Seifriedsberger, the general manager for Women’s Health, Advanced Visualization Solutions at GE HealthCare. “By introducing solutions that offer unparalleled clarity and detail, we can empower users with critical insights for informed care decisions and efficient exams, transforming how clinicians approach health care.”
Emerging AI Software for Prostate MRI Offers 95 Percent Sensitivity for csPCa
February 28th 2025In a multicenter study involving over 1,000 patients, a deep learning software offered comparable sensitivity and specificity for Gleason grade group > 2 tumors in comparison to radiologist interpretation.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can CT-Based AI Help Predict Renal Function Decline After Radioligand Therapy for mCRPC?
February 25th 2025In patients who had at least four cycles of 177Lu-PSMA-I&T for mCRPC, new research shows that a 10 percent or greater decrease in total kidney volume on CT at six months has a 90 percent AUC for predicting estimated glomerular filtration rates (eGFRs) of 30 percent or greater at one year.